VRNA has been in the news 1000% more than usual
Jul 09, 2025, 4:32 PM
0.09%
What does VRNA do
Verona Pharma Plc develops therapeutics for respiratory diseases, focusing on its investigational inhaled drug, ensifentrine, for chronic obstructive pulmonary disease (COPD). Two additional formulations of ensifentrine are in Phase II development.
VRNA has been in the news recently: Merck & Co. Inc. is set to acquire Verona Pharma plc for $107 per American Depository Share (ADS), amounting to approximately $10 billion. This acquisition is part of a larger trend of rising U.S. stocks, as indicated by the increase in the Dow Jones index.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.